Aikai Biotech

Aikai Biotech (艾凯利元/艾凯生物) is a Suzhou-based biotech company developing next-generation universal off-the-shelf cell therapies using iPSC (inducible pluripotent stem cell) technology . In its first year of operation, the company completed three funding rounds, including an A+ round of over 200 million yuan . Its investors include 5Y Capital, Linknew Capital, Xihu Innovation Investment, Kaifeng Investment, Delian Capital, and others . A 5Y Capital vice president framed iPSC-derived cells as potentially becoming important "infrastructure" for cell therapy, with applications in tumor immunotherapy and regenerative medicine . elsewhere's corpus does not cover more recent developments beyond 2022.